Evidence map›Paper›PMID 31764816›Full record

ArticleMedicine2019

Undetectable proviral deoxyribonucleic acid in an adolescent perinatally infected with human immunodeficiency virus-1C and on long-term antiretroviral therapy resulted in viral rebound following antiretroviral therapy termination: A case report with implications for clinical care.

Catherine Kegakilwe Koofhethile, Sikhulile Moyo, Kenanao Peggy Kotokwe, Patrick Mokgethi, Lorato Muchoba, Selebogo Mokgweetsi, Tendani Gaolathe, Joseph Makhema, Roger Shapiro, Shahin Lockman and 5 more

Abstract readCase Reports
In one paragraph

Article in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Catherine Kegakilwe KoofhethileBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Sikhulile MoyoBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Kenanao Peggy KotokweBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Patrick MokgethiBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Lorato MuchobaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Selebogo MokgweetsiBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Tendani GaolatheBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Joseph MakhemaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Roger ShapiroBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Shahin LockmanBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Phyllis KankiHarvard T.H. Chan School of Public Health, Boston, MA.
M EssexBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Simani GaseitsiweBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Tulio de OliveiraCollege of Health Sciences, Nelson R Mandela School of Medicine, University of KwaZulu-Natal (UKZN).
Vladimir NovitskyBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.

Funding

Partnership for Global Health Research Training Program (Renewal)-Supplement for OBSSR, NCI, NCI-AIDS and NIDCDD43TW010543 · FIC · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Wafaie W Fawzi, DAVIDSON HOWES HAMER · 2017 to 2026
$12.1M
Training in HIV Genomics, Treatment, and Cure Research in BotswanaD43TW009610 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI SHAHIN LOCKMAN, Joseph Moeketsi Makhema · 2013 to 2026
$4.4M
FIC NIH HHS D43 TW009610FIC NIH HHS D43 TW010543Wellcome Trust
6 · The paper itself

Abstract

rationaleEarly initiation of antiretroviral therapy (ART) leads to long-term viral suppression, reduces proviral reservoir size, and prolongs time to rebound. Since human immunodeficiency virus (HIV) is a lifelong disease, diagnostic monitoring after confirmed infection is typically not performed; therefore, little is known about the impact of early initiation and long-term ART on the sensitivity of assays that detect HIV antibodies and viral nucleic acid in children and adolescents. PATIENT CONCERNS: Here we report 1 case of diagnosed and confirmed perinatal HIV-1C infection with longstanding viral suppression, who subsequently had a negative HIV-1 deoxyribonucleic acid (DNA) test, undetectable antibodies to HIV-1, and high CD4+ T cell count after 14 years of ART. DIAGNOSIS: The patient was diagnosed with HIV in 2002 at 1 and 2 months of age using DNA polymerase chain reaction. At 8 months old, his viral load was 1210 HIV ribonucleic acid (RNA) copies/mL and CD4 T cell count was 3768 cells/mm.

interventionAt the age of 9 months, highly active antiretroviral therapy comprising of zidovudine, nevirapine, and lamivudine was initiated. The patient remained on this treatment for 14 years 11 months and was virally suppressed. OUTCOMES: At the age of 14 years 4 months, the participant decided to visit a local voluntary HIV testing center, where a rapid HIV test came out negative and the viral load was undetectable (<400 HIV-1 RNA copies/mL). These results led to termination of ART which led to viral rebound within 9 months. LESSONS: As more people with early HIV infection initiate early ART in the context of "Test and Treat all" recommendations, aspects of this report may become more commonplace, with both clinical and public health implications. If the possibility of functional cure (or false-positive diagnosis) is being considered, decisions to terminate ART should be made cautiously and with expert guidance, and may benefit from highly sensitive quantification of the proviral reservoir.

Indexed as

Antiretroviral Therapy, Highly ActiveVirus ActivationAdolescentDNA, ViralFollow-Up StudiesHIV-1HIV InfectionsHumansInfant, NewbornMaleProvirusesTime FactorsWithholding TreatmentDNA, Viral

Identifiers

PMID31764816
PMCPMC6882625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.